Finally, in patients with dementia taking cholinesterase inhibitors, new use of oxybutynin or tolterodine resulted in a higher rate of functional decline than for patients with dementia who used cholinesterase inhibitors alone [23]. This evidence concerns the gene BCHE and dementia.